Alzheimer’s Disease Deserves A Data-Driven Paradigm Shift
36 million people worldwide are affected by Alzheimer’s disease. What’s the future outlook of emerging treatments and early disease diagnostics?
Billions of dollars have been invested in Alzheimer’s disease (AD) research, and there have been hundreds of failed drugs. As the financial and health impact of AD on patients, caregivers, and healthcare systems continues to rise, the urgency for new treatments is mounting.
Using our Pharma Playbook data analytics platform, this white paper zooms in on the data to reveal some of the important lessons learned, and promising signals of a turnaround, on the path to solving the AD epidemic.
This in-depth white paper utilizes Pharma Playbook’s powerful analytic engines, such as the Medical Condition ScoreCard, Medical Condition Opportunity Assessment, and others, to connect and uncover data-driven insights that examine the future outlook of emerging treatments and early disease diagnostics.